Toward identifying key mechanisms of progression in multiple sclerosis

Trends Neurosci. 2023 Dec 14:S0166-2236(23)00265-5. doi: 10.1016/j.tins.2023.11.005. Online ahead of print.ABSTRACTA major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the accumulation of disability over an often decades-long disease course. Disability progression can result from acute relapses as well as from CNS intrinsic parenchymal disintegration without de novo CNS lesion formation. Research focus has shifted to progression not associated with acute inflammation, as it is not sufficiently controlled by currently available treatments. This review outlines how recent advances in the understanding of the pathogenesis of progressive MS have been facilitated by the development of more precise, less static pathogenetic concepts of progressive MS, as well as by new techniques for the analysis of region-specific proteomic and transcriptomic signatures in the human CNS. We highlight key drivers of MS disease progression and potential targets in its treatment.PMID:38102058 | DOI:10.1016/j.tins.2023.11.005
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research